280Bio, a Yingli Pharma Subsidiary, to Start US Trials of RAS Inhibitor

280Bio, a South San Francisco precision oncology biotech, was approved to start US trials of a small molecule inhibitor of RAS signaling. In preclinical studies, YL-17231 showed strong inhibition in a variety of RAS mutations, including tumors that have become resistant to KRAS G12C inhibitors, according to 280Bio. KRAS, NRAS and HRAS genes are frequently mutated in tumors, leading to tumor cell growth. 280Bio claims YL-17231 has broader activity than currently available KRAS inhibitors 280Bio, a wholly owned subsidiary of Shanghai Yingli Pharma, developed YL-17231 with Yingli in collaboration with The University of Texas MD Anderson Cancer Center. More details....

Share this with colleagues: